glycine has been researched along with Kidney Failure in 14 studies
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
Excerpt | Relevance | Reference |
---|---|---|
"We assayed the redox forms of cysteine (reduced [CSH], oxidized [CSSC], and bound to protein [CS-SP]), cysteinylglycine (CGSH; cysteinylgycine disulfide [CGSSGC] and cysteinylglycine-protein mixed disulfide [CGS-SP]), glutathione (GSH; glutathione disulfide [GSSG] and glutathione-protein mixed disulfide [GS-SP]), homocysteine (Hcy; homocystine [HcyS] and homocystine-protein mixed disulfides [bHcy]), and protein sulfhydryls in the plasma of healthy subjects (divided into 8 groups ranging in age from birth to 70 years) and patients with mild hyperhomocysteinemia associated with cardiovascular disease (heart-transplant patients) or vascular atherosclerosis, with or without renal failure." | 7.72 | The effects of age and hyperhomocysteinemia on the redox forms of plasma thiols. ( Buonocore, G; Capecchi, PL; Cellesi, C; Di Giuseppe, D; Di Simplicio, FC; Di Simplicio, P; Frosali, S; Jakubowski, H; Lazzerini, PE; Pasini, FL; Priora, R, 2004) |
" PK and adverse events (AEs) were assessed after a single 3 mg dose of ixazomib." | 6.82 | A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis. ( Badros, A; Berdeja, J; Chari, A; Gupta, N; Hanley, MJ; Harvey, RD; Hui, AM; Kukreti, V; Lipe, B; Qian, M; Venkatakrishnan, K; Yang, H; Zhang, X, 2016) |
" Guanidinosuccinate correlated positively with plasma urea and negatively with inflammation markers." | 5.13 | Guanidino compounds after creatine supplementation in renal failure patients and their relation to inflammatory status. ( De Deyn, PP; De Vriese, A; Delanghe, JR; Marescau, B; Schepers, E; Taes, YE; Vanholder, R, 2008) |
"We assayed the redox forms of cysteine (reduced [CSH], oxidized [CSSC], and bound to protein [CS-SP]), cysteinylglycine (CGSH; cysteinylgycine disulfide [CGSSGC] and cysteinylglycine-protein mixed disulfide [CGS-SP]), glutathione (GSH; glutathione disulfide [GSSG] and glutathione-protein mixed disulfide [GS-SP]), homocysteine (Hcy; homocystine [HcyS] and homocystine-protein mixed disulfides [bHcy]), and protein sulfhydryls in the plasma of healthy subjects (divided into 8 groups ranging in age from birth to 70 years) and patients with mild hyperhomocysteinemia associated with cardiovascular disease (heart-transplant patients) or vascular atherosclerosis, with or without renal failure." | 3.72 | The effects of age and hyperhomocysteinemia on the redox forms of plasma thiols. ( Buonocore, G; Capecchi, PL; Cellesi, C; Di Giuseppe, D; Di Simplicio, FC; Di Simplicio, P; Frosali, S; Jakubowski, H; Lazzerini, PE; Pasini, FL; Priora, R, 2004) |
" PK and adverse events (AEs) were assessed after a single 3 mg dose of ixazomib." | 2.82 | A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis. ( Badros, A; Berdeja, J; Chari, A; Gupta, N; Hanley, MJ; Harvey, RD; Hui, AM; Kukreti, V; Lipe, B; Qian, M; Venkatakrishnan, K; Yang, H; Zhang, X, 2016) |
"Alport syndrome is the commonest inherited kidney disease and nearly half the pathogenic variants in the COL4A3-COL4A5 genes that cause Alport syndrome result in Gly substitutions." | 1.72 | Genotype-phenotype correlations for COL4A3-COL4A5 variants resulting in Gly substitutions in Alport syndrome. ( Cerkauskaite, A; Chan, MMY; Deltas, C; Gale, DP; Gibson, JT; Hilbert, P; Huang, M; Lipska-Ziętkiewicz, BS; Rothe, H; Sadeghi-Alavijeh, O; Savige, J; Shenelli Croos Dabrera, M; Shukla, K; Storey, H, 2022) |
"Salt-induced hypertension is one of the major issues worldwide and one of the main factors involved in heart and kidney failure." | 1.72 | Benincasa hispida extracts positively regulated high salt-induced hypertension in Dahl salt-sensitive rats: Impact on biochemical profile and metabolic patterns. ( Ahmad, H; Ahmad, N; Chen, M; Du, J; Jin, Y; Khan, A; Li, X; Ouyang, Y; Tian, Z; Yang, P; Yang, Z; Zeng, L; Zhao, X; Zheng, X, 2022) |
"Over 80% of chronic renal failure patients have elevated plasma Hcy and a 10-20 times higher incidence of vascular disease." | 1.34 | Dimethylthetin treatment causes diffuse alveolar lung damage: a pilot study in a sheep model of Continuous Ambulatory Peritoneal Dialysis (CAPD). ( Chambers, S; Fraser, R; George, P; Lever, M; McEntyre, C; Slow, S; Vasudevamurthy, M, 2007) |
"A model of renal failure has been developed in male C57BL x Swiss-Webster mice using nephrectomy (NX) and/or arterial ligation." | 1.30 | Biochemical and histopathological changes in nephrectomized mice. ( Al Banchaabouchi, M; D'Hooge, R; De Deyn, PP; Levillain, O; Marescau, B; Van Daele, A; Van Marck, E, 1998) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (7.14) | 18.7374 |
1990's | 2 (14.29) | 18.2507 |
2000's | 3 (21.43) | 29.6817 |
2010's | 4 (28.57) | 24.3611 |
2020's | 4 (28.57) | 2.80 |
Authors | Studies |
---|---|
Gibson, JT | 1 |
Huang, M | 1 |
Shenelli Croos Dabrera, M | 1 |
Shukla, K | 1 |
Rothe, H | 1 |
Hilbert, P | 1 |
Deltas, C | 1 |
Storey, H | 1 |
Lipska-Ziętkiewicz, BS | 1 |
Chan, MMY | 1 |
Sadeghi-Alavijeh, O | 1 |
Gale, DP | 1 |
Cerkauskaite, A | 1 |
Savige, J | 1 |
Vigers, T | 1 |
Vinovskis, C | 1 |
Li, LP | 1 |
Prasad, P | 1 |
Heerspink, H | 1 |
D'Alessandro, A | 1 |
Reisz, JA | 1 |
Piani, F | 1 |
Cherney, DZ | 1 |
van Raalte, DH | 1 |
Nadeau, KJ | 1 |
Pavkov, ME | 1 |
Nelson, RG | 1 |
Pyle, L | 1 |
Bjornstad, P | 1 |
Ahmad, H | 1 |
Zhao, X | 1 |
Ahmad, N | 1 |
Khan, A | 1 |
Jin, Y | 1 |
Du, J | 1 |
Zheng, X | 1 |
Zeng, L | 1 |
Ouyang, Y | 1 |
Yang, P | 1 |
Chen, M | 1 |
Li, X | 1 |
Yang, Z | 1 |
Tian, Z | 1 |
Ichii, M | 1 |
Mori, K | 1 |
Miyaoka, D | 1 |
Sonoda, M | 1 |
Tsujimoto, Y | 1 |
Nakatani, S | 1 |
Shoji, T | 1 |
Emoto, M | 1 |
Gu, L | 1 |
Wang, X | 1 |
Zhang, Y | 1 |
Jiang, Y | 1 |
Lu, H | 1 |
Bi, K | 1 |
Chen, X | 1 |
Gupta, N | 1 |
Hanley, MJ | 1 |
Harvey, RD | 1 |
Badros, A | 1 |
Lipe, B | 1 |
Kukreti, V | 1 |
Berdeja, J | 1 |
Yang, H | 1 |
Hui, AM | 1 |
Qian, M | 1 |
Zhang, X | 1 |
Venkatakrishnan, K | 1 |
Chari, A | 1 |
Diercks, DB | 1 |
Owen, K | 1 |
Tolstikov, V | 1 |
Sutter, M | 1 |
Zouaoui, K | 1 |
Dulaurent, S | 1 |
Gaulier, JM | 1 |
Moesch, C | 1 |
Lachâtre, G | 1 |
ROSENTHAL, IM | 1 |
GABALLAH, S | 1 |
RAFELSON, ME | 1 |
Di Giuseppe, D | 1 |
Frosali, S | 1 |
Priora, R | 1 |
Di Simplicio, FC | 1 |
Buonocore, G | 1 |
Cellesi, C | 1 |
Capecchi, PL | 1 |
Pasini, FL | 1 |
Lazzerini, PE | 1 |
Jakubowski, H | 1 |
Di Simplicio, P | 1 |
Slow, S | 1 |
Vasudevamurthy, M | 1 |
Fraser, R | 1 |
McEntyre, C | 1 |
Lever, M | 1 |
Chambers, S | 1 |
George, P | 1 |
Taes, YE | 1 |
Marescau, B | 2 |
De Vriese, A | 1 |
De Deyn, PP | 2 |
Schepers, E | 1 |
Vanholder, R | 1 |
Delanghe, JR | 1 |
Dogan, AS | 1 |
Kirchner, PT | 1 |
Al Banchaabouchi, M | 1 |
D'Hooge, R | 1 |
Van Marck, E | 1 |
Van Daele, A | 1 |
Levillain, O | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
CASPER Study: Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function[NCT03618420] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study[NCT03584217] | Phase 1/Phase 2 | 100 participants (Actual) | Interventional | 2018-10-01 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Measured by fasting blood draw; Copeptin will be measured by ultrasensitive assays on KRYPTOR Compact Plus analyzers using the commercial sandwich immunoluminometric assays (Thermo Fisher Scientific, Waltham, MA). The copeptin assay has a lower limit of detection of 0.9 pmol/L, and a sensitivity of <2pmol/L. Elevated copeptin will be defined as >13pmol/L, which is >97.5th percentile for healthy adults (68). (NCT03618420)
Timeframe: 4 hours
Intervention | pmol/L (Mean) |
---|---|
Clinical Investigation | 8.3 |
Measured by para-aminohippurate (PAH) clearance; An intravenous (IV) line was placed, and participants were asked to empty their bladders. Spot plasma and urine samples were collected prior PAH infusion. PAH (2 g/10 mL, prepared at the University of Minnesota, with a dose of [weight in kg]/75 × 4.2 mL; IND #140129) was given slowly over 5 min followed by a continuous infusion of 8 mL of PAH and 42 mL of normal saline at a rate of 24 mL/h for 2 h. After an equilibration period, blood was drawn at 90 and 120 min, and ERPF was calculated as PAH clearance divided by the estimated extraction ratio of PAH, which varies by the level of GFR (13). We report absolute ERPF (mL/min) in the main analyses because the practice of indexing ERPF for body surface underestimates hyperperfusion, and body surface area (BSA) calculations introduce noise into the clearance measurements. (NCT03618420)
Timeframe: 4 hours
Intervention | ml/min (Mean) |
---|---|
Clinical Investigation | 820 |
Measured by iohexol clearance; An intravenous (IV) line was placed, and participants were asked to empty their bladders. Spot plasma and urine samples were collected prior to iohexol infusion. Iohexol was administered through bolus IV injection (5 mL of 300 mg/mL; Omnipaque 300, GE Healthcare). An equilibration period of 120 min was used and blood collections for iohexol plasma disappearance were drawn at +120, +150, +180, +210, +240 min (11). Because the Brøchner-Mortensen equation underestimates high values of GFR, the Jødal-Brøchner-Mortensen equation was used to calculate the GFR (12). We report absolute GFR (mL/min) in the main analyses because the practice of indexing GFR for body surface underestimates hyperfiltration, and body surface area (BSA) calculations introduce noise into the clearance measurements. (NCT03618420)
Timeframe: 4 hours
Intervention | ml/min (Mean) |
---|---|
Clinical Investigation | 189 |
Measured by Blood Oxygen Level Dependent (BOLD) MRI; Regions of interest (ROI) analysis for BOLD MRI will be performed on a Leonardo Workstation (Siemens Medical Systems, Germany). Typically, 1 to 3 regions in each, cortex and medulla, per kidney per slice will be defined leading to a total of about 10 ROIs per region (cortex and medulla) per subject. The mean and standard deviation of these 10 measurements will be used a R2* measurement for the region, for the subject and for that time point. These data are used to calculate kidney oxygen availability (R2*), which is the BOLD-MRI outcome. (NCT03618420)
Timeframe: 60 min
Intervention | s^-1 (Mean) |
---|---|
Clinical Investigation | 22.7 |
Measured by Arterial Spin Labeling (ASL) MRI; ASL MRI: ROI analysis will be used to estimate (delta) M (difference in signal intensity between non-selective and selective inversion images). Using the same ROI, M0 will be estimated from the proton density image. T1 measurements from the same ROI will be obtained by fitting the signal intensity vs. inversion time data as described previously (104) using XLFit (ID Business Solutions Ltd., UK) or T1 maps created using MRI Mapper (Beth Israel Deaconess Medical Center, Boston). Partition coefficient will be assumed to be 0.8 ml/gm (105, 106). These values will then be used to estimate regional blood flow. (NCT03618420)
Timeframe: 10 min
Intervention | ml/min/100g (Mean) |
---|---|
Clinical Investigation | 180 |
3 trials available for glycine and Kidney Failure
Article | Year |
---|---|
Plasma levels of carboxylic acids are markers of early kidney dysfunction in young people with type 1 diabetes.
Topics: Adolescent; Albuminuria; Carboxylic Acids; Diabetes Mellitus, Type 1; Fumarates; Glomerular Filtrati | 2023 |
Plasma levels of carboxylic acids are markers of early kidney dysfunction in young people with type 1 diabetes.
Topics: Adolescent; Albuminuria; Carboxylic Acids; Diabetes Mellitus, Type 1; Fumarates; Glomerular Filtrati | 2023 |
Plasma levels of carboxylic acids are markers of early kidney dysfunction in young people with type 1 diabetes.
Topics: Adolescent; Albuminuria; Carboxylic Acids; Diabetes Mellitus, Type 1; Fumarates; Glomerular Filtrati | 2023 |
Plasma levels of carboxylic acids are markers of early kidney dysfunction in young people with type 1 diabetes.
Topics: Adolescent; Albuminuria; Carboxylic Acids; Diabetes Mellitus, Type 1; Fumarates; Glomerular Filtrati | 2023 |
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Blood Proteins; Boron Compounds; Drug | 2016 |
Guanidino compounds after creatine supplementation in renal failure patients and their relation to inflammatory status.
Topics: Administration, Oral; Aged; Arginine; Biomarkers; C-Reactive Protein; Creatine; Cross-Over Studies; | 2008 |
11 other studies available for glycine and Kidney Failure
Article | Year |
---|---|
Genotype-phenotype correlations for COL4A3-COL4A5 variants resulting in Gly substitutions in Alport syndrome.
Topics: Adult; Amino Acid Substitution; Autoantigens; Collagen Type IV; Databases, Genetic; Deafness; Female | 2022 |
Benincasa hispida extracts positively regulated high salt-induced hypertension in Dahl salt-sensitive rats: Impact on biochemical profile and metabolic patterns.
Topics: Alanine; Amino Acids; Animals; Antihypertensive Agents; Antioxidants; Aspartic Acid; Cucurbitaceae; | 2022 |
Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis.
Topics: Aged; Anemia; Glycine; Humans; Isoquinolines; Male; Renal Dialysis; Renal Insufficiency; Thyrotropin | 2021 |
Determination of 12 potential nephrotoxicity biomarkers in rat serum and urine by liquid chromatography with mass spectrometry and its application to renal failure induced by Semen Strychni.
Topics: Animals; Biomarkers; Chromatography, Liquid; Citric Acid; Creatinine; Drugs, Chinese Herbal; Glycine | 2014 |
Urinary metabolomic analysis for the identification of renal injury in patients with acute heart failure.
Topics: Aged; Biomarkers; Creatinine; Discriminant Analysis; Female; Gas Chromatography-Mass Spectrometry; G | 2012 |
Determination of glyphosate and AMPA in blood and urine from humans: about 13 cases of acute intoxication.
Topics: Accidents; Acidosis; Adult; Aged; Arrhythmias, Cardiac; Chemical and Drug Induced Liver Injury; Chro | 2013 |
GOUT IN INFANCY MANIFESTED BY RENAL FAILURE.
Topics: Acute Kidney Injury; Adolescent; Blood Cell Count; Child; Citrates; Genetics, Medical; Glycine; Gout | 1964 |
The effects of age and hyperhomocysteinemia on the redox forms of plasma thiols.
Topics: Adolescent; Adult; Aged; Aging; Arteriosclerosis; Blood Proteins; Cardiovascular Diseases; Child; Ch | 2004 |
Dimethylthetin treatment causes diffuse alveolar lung damage: a pilot study in a sheep model of Continuous Ambulatory Peritoneal Dialysis (CAPD).
Topics: Animals; Betaine; Betaine-Homocysteine S-Methyltransferase; Dialysis Solutions; Disease Models, Anim | 2007 |
Hepatobiliary excretion of MAG3. Simulation of a urinary leak.
Topics: Aniline Compounds; Glycine; Humans; Imino Acids; Male; Middle Aged; Organotechnetium Compounds; Radi | 1993 |
Biochemical and histopathological changes in nephrectomized mice.
Topics: Animals; Arginine; Brain; Creatinine; Glycine; Guanidine; Guanidines; Ligation; Male; Mice; Mice, In | 1998 |